Propofol-Fentanyl-Dexmedetomidine & Propofol-Fentanyl-Sevoflurane

Status Recruiting

Clinical Trial Summary

The objective of this study is to evaluate the effect of adding dexmedetomidine on evoked potentials in adult patients undergoing spinal surgery under intravenous anesthesia

Clinical Trial Description

A catastrophic complication of spinal surgery is nerve and spinal cord injury. The incidence of neurological defects after spinal surgery can be reduced from 3.7%-6.9% to less than 1% with proper electrophysiological monitoring. Somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) are currently used as adjunct diagnostic methods in spinal surgery, such as scoliosis surgery and spinal stenosis decompression. Total intravenous anesthesia (TIVA) with propofol and opioids is commonly used in SEPs and MEPs monitoring as it causes increase in latency in comparison to inhalational anesthetics that cause decrease in amplitude . The amplitudes of MEPs and SEPs are reduced by halogenated volatile anesthetics, limiting their use in spinal surgery that requires electrophysiological monitoring. When volatile anesthetics did not exceed 0.3MAC, they had little effect on MEPs and SEPs . Martin et al. discovered that volatile agent-based anesthesia has application value during neurophysiological monitoring, such as faster awakening and rapid wake-up tests. As well, volatile anesthetics can reduce the dosage of propofol. As a result, spinal surgery benefits from combined intravenous inhalation anesthesia. As an adjuvant, dexmedetomidine may be useful in reducing the need for propofol. Dexmedetomidine is a potent and highly selective alpha-2 agonist. It has the effect of sedation, analgesia, sympatholytic, minimal respiratory depression and possible neuroprotection. Its addition to the anesthetic regimen is believed to have the potential of sparing other hypnotics requirement, especially propofol, thus facilitating MEP and SSEP monitoring while providing the beneficial effects it has. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06210061
Study type	Interventional
Source	Ain Shams University
Contact	Mohamed I Shahin, Master
Phone	00201024556447
Email	mohamed.i.shahin@med.asu.edu.eg
Status	Recruiting
Phase	N/A
Start date	September 1, 2023
Completion date	September 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04577430` - Effects of Dexmedetomidine on Cardiac Electrophysiology in Patients Under General Anesthesia During Perioperative Period	N/A
Completed	`NCT03220880` - Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
Completed	`NCT05291364` - Dexmedetomidine in Splanchnic Nerve Neurolysis	N/A
Recruiting	`NCT05249153` - Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery	N/A
Completed	`NCT01688648` - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft	N/A
Completed	`NCT05103735` - Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
Recruiting	`NCT06030804` - Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery	N/A
Terminated	`NCT03253224` - Magnesium and Postoperative Pain	Phase 4
Recruiting	`NCT05525819` - Intrathecal Versus Intravenous Dexmedetomidine in Prostate Transurethral Resection	N/A
Completed	`NCT04665453` - Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children	N/A
Completed	`NCT06018948` - Effect of Two Different Doses of Dexmedetomidine Infusion in Morbidly Obese Patients	Phase 4
Completed	`NCT03775655` - Low Dose Hyperbaric Bupivacaine and Dexmedetomidine as an Adjuvant, Caesarean Section	Phase 2/Phase 3
Completed	`NCT03658421` - Dexmedetomidine as Adjuvant for FNB in TKA	N/A
Completed	`NCT03234660` - Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia	N/A
Completed	`NCT06020781` - Efficacy and Safety of Dexmedetomidine to Bupivacaine in Supraclavicular Brachial Plexus Block	N/A
Recruiting	`NCT06207331` - Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease	N/A
Active, not recruiting	`NCT03629262` - Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery	Phase 4
Completed	`NCT06098209` - Dexmedetomidine and Propofol in Mechanically Ventilated Patients by Using Salivary Alpha-amylase as a Stress Marker	N/A
Not yet recruiting	`NCT06062550` - Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery	Phase 4
Completed	`NCT02211118` - Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Propofol-Fentanyl-Dexmedetomidine and Propofol-Fentanyl-Sevoflurane Anesthesia for Major Spine Surgery Under Somato Sensory- and Motor- Evoked Potential Monitoring

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms